tiprankstipranks
Trending News
More News >
VYNE Therapeutics (VYNE)
NASDAQ:VYNE
US Market

VYNE Therapeutics (VYNE) Income Statement

Compare
1,903 Followers

VYNE Therapeutics Income Statement

Last quarter (Q3 2025), VYNE Therapeutics's total revenue was $169.00K, an increase of 39.67% from the same quarter last year. In Q3, VYNE Therapeutics's net income was $-7.28M. See VYNE Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 501.00K$ 424.00K$ 477.00K$ 931.00K$ 20.99M
Gross Profit
$ 501.00K$ 424.00K$ 477.00K$ 931.00K$ 19.60M
Operating Expenses
$ 44.14M$ 29.68M$ 34.77M$ 39.84M$ -232.94M
Depreciation and Amortization
$ 4.00K$ 0.00$ 72.00K$ 109.00K$ 341.00K
EBITDA
$ -43.63M$ -29.26M$ -34.22M$ -38.80M$ -251.09M
Operating Income
$ -43.64M$ -29.26M$ -34.30M$ -38.91M$ 252.55M
Other Income/Expenses
$ 3.83M$ 1.39M$ 363.00K$ -4.85M$ -508.37M
Pretax Income
$ -39.80M$ -27.87M$ -33.93M$ -43.76M$ -255.83M
Net Income
$ -39.83M$ -28.45M$ -23.21M$ -73.33M$ -255.57M
Per Share Metrics
Basic EPS
$ -0.93$ -2.77$ -10.65$ -25.65$ -141.90
Diluted EPS
$ -0.93$ -2.77$ -10.65$ -25.65$ -141.90
Weighted Average Shares Outstanding
42.59M 10.27M 3.19M 2.86M 1.80M
Weighted Average Shares Outstanding (Diluted)
42.59M 10.27M 3.19M 2.86M 1.80M
Currency in USD

VYNE Therapeutics Earnings and Revenue History